Search

Your search keyword '"Lauria, Francesco"' showing total 38 results
Start Over Author "Lauria, Francesco" Publisher wiley
38 results on '"Lauria, Francesco"'

1. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients

Author

Foà, Robin, primary, Del Giudice, Ilaria, additional, Cuneo, Antonio, additional, Del Poeta, Giovanni, additional, Ciolli, Stefania, additional, Di Raimondo, Francesco, additional, Lauria, Francesco, additional, Cencini, Emanuele, additional, Rigolin, Gian Matteo, additional, Cortelezzi, Agostino, additional, Nobile, Francesco, additional, Callea, Vincenzo, additional, Brugiatelli, Maura, additional, Massaia, Massimo, additional, Molica, Stefano, additional, Trentin, Livio, additional, Rizzi, Rita, additional, Specchia, Giorgina, additional, Di Serio, Francesca, additional, Orsucci, Lorella, additional, Ambrosetti, Achille, additional, Montillo, Marco, additional, Zinzani, Pier Luigi, additional, Ferrara, Felicetto, additional, Morabito, Fortunato, additional, Mura, Maria Angela, additional, Soriani, Silvia, additional, Peragine, Nadia, additional, Tavolaro, Simona, additional, Bonina, Silvia, additional, Marinelli, Marilisa, additional, De Propris, Maria Stefania, additional, Starza, Irene Della, additional, Piciocchi, Alfonso, additional, Alietti, Alessandra, additional, Runggaldier, Eva Josephine, additional, Gamba, Enrica, additional, Mauro, Francesca Romana, additional, Chiaretti, Sabina, additional, and Guarini, Anna, additional

Published
2014
Full Text
View/download PDF

2. Evaluation of residual CD34+Ph+progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy

Author

Defina, Marzia, primary, Ippoliti, Micaela, additional, Gozzetti, Alessandro, additional, Abruzzese, Elisabetta, additional, Castagnetti, Fausto, additional, Crupi, Rosaria, additional, Tiribelli, Mario, additional, Breccia, Massimo, additional, Salvucci, Marzia, additional, Aprile, Lara, additional, Baratè, Claudia, additional, Gozzini, Antonella, additional, Rosti, Gianantonio, additional, Lauria, Francesco, additional, and Bocchia, Monica, additional

Published
2012
Full Text
View/download PDF

3. Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia

Author

Bulian, Pietro, primary, Tarnani, Michela, additional, Rossi, Davide, additional, Forconi, Francesco, additional, Del Poeta, Giovanni, additional, Bertoni, Francesco, additional, Zucca, Emanuele, additional, Montillo, Marco, additional, Pozzato, Gabriele, additional, Deaglio, Silvia, additional, D'Arena, Giovanni, additional, Efremov, Dimitar, additional, Marasca, Roberto, additional, Lauria, Francesco, additional, Gattei, Valter, additional, Gaidano, Gianluca, additional, and Laurenti, Luca, additional

Published
2011
Full Text
View/download PDF

6. Oxaliplatin‐based chemotherapy (dexamethasone, high‐dose cytarabine, and oxaliplatin) ± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma

Author

Rigacci, Luigi, primary, Fabbri, Alberto, additional, Puccini, Benedetta, additional, Chitarrelli, Ida, additional, Chiappella, Annalisa, additional, Vitolo, Umberto, additional, Levis, Alessandro, additional, Lauria, Francesco, additional, and Bosi, Alberto, additional

Published
2010
Full Text
View/download PDF

7. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)

Author

Amadori, Sergio, primary, Suciu, Stefan, additional, Selleslag, Dominik, additional, Stasi, Roberto, additional, Alimena, Giuliana, additional, Baila, Liliana, additional, Rizzoli, Vittorio, additional, Borlenghi, Erika, additional, Gaidano, Gianluca, additional, Magro, Domenico, additional, Torelli, Giuseppe, additional, Muus, Petra, additional, Venditti, Adriano, additional, Cacciola, Emma, additional, Lauria, Francesco, additional, Vignetti, Marco, additional, and de Witte, Theo, additional

Published
2010
Full Text
View/download PDF

9. Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance

Author

Breccia, Massimo, primary, Bocchia, Monica, additional, Cannella, Laura, additional, Defina, Marzia, additional, Ippoliti, Micaela, additional, Loglisci, Giuseppina, additional, Santopietro, Michelina, additional, Lauria, Francesco, additional, and Alimena, Giuliana, additional

Published
2010
Full Text
View/download PDF

11. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors

Author

Rossi, Davide, primary, Sozzi, Elisa, additional, Puma, Alessia, additional, De Paoli, Lorenzo, additional, Rasi, Silvia, additional, Spina, Valeria, additional, Gozzetti, Alessandro, additional, Tassi, Maristella, additional, Cencini, Emanuele, additional, Raspadori, Donatella, additional, Pinto, Valeria, additional, Bertoni, Francesco, additional, Gattei, Valter, additional, Lauria, Francesco, additional, Gaidano, Gianluca, additional, and Forconi, Francesco, additional

Published
2009
Full Text
View/download PDF

12. Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

Author

Else, Monica, primary, Dearden, Claire E., additional, Matutes, Estella, additional, Garcia‐Talavera, Juan, additional, Rohatiner, Ama Z. S., additional, Johnson, Steve A. N., additional, O’Connor, Nigel T. J., additional, Haynes, Andy, additional, Osuji, Nnenna, additional, Forconi, Francesco, additional, Lauria, Francesco, additional, and Catovsky, Daniel, additional

Published
2009
Full Text
View/download PDF

14. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study

Author

Bomben, Riccardo, primary, Dal Bo, Michele, additional, Capello, Daniela, additional, Forconi, Francesco, additional, Maffei, Rossana, additional, Laurenti, Luca, additional, Rossi, Davide, additional, Del Principe, Maria Ilaria, additional, Zucchetto, Antonella, additional, Bertoni, Francesco, additional, Rossi, Francesca Maria, additional, Bulian, Pietro, additional, Cattarossi, Ilaria, additional, Ilariucci, Fiorella, additional, Sozzi, Elisa, additional, Spina, Valeria, additional, Zucca, Emanuele, additional, Degan, Massimo, additional, Lauria, Francesco, additional, Del Poeta, Giovanni, additional, Efremov, Dimitar G., additional, Marasca, Roberto, additional, Gaidano, Gianluca, additional, and Gattei, Valter, additional

Published
2009
Full Text
View/download PDF

16. Genome‐wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion

Author

Forconi, Francesco, primary, Rinaldi, Andrea, additional, Kwee, Ivo, additional, Sozzi, Elisa, additional, Raspadori, Donatella, additional, Rancoita, Paola M. V., additional, Scandurra, Marta, additional, Rossi, Davide, additional, Deambrogi, Clara, additional, Capello, Daniela, additional, Zucca, Emanuele, additional, Marconi, Daniela, additional, Bomben, Riccardo, additional, Gattei, Valter, additional, Lauria, Francesco, additional, Gaidano, Gianluca, additional, and Bertoni, Francesco, additional

Published
2008
Full Text
View/download PDF

17. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases

Author

Malagola, Michele, primary, Peli, Annalisa, additional, Damiani, Daniela, additional, Candoni, Anna, additional, Tiribelli, Mario, additional, Martinelli, Giovanni, additional, Piccaluga, Pier Paolo, additional, Paolini, Stefania, additional, De Rosa, Francesco, additional, Lauria, Francesco, additional, Bocchia, Monica, additional, Gobbi, Marco, additional, Pierri, Ivana, additional, Zaccaria, Alfonso, additional, Zuffa, Eliana, additional, Mazza, Patrizio, additional, Priccolo, Giancarla, additional, Gugliotta, Luigi, additional, Bonini, Alessandro, additional, Visani, Giuseppe, additional, Skert, Cristina, additional, Bergonzi, Cesare, additional, Roccaro, Aldo Maria, additional, Filì, Carla, additional, Fanin, Renato, additional, Baccarani, Michele, additional, and Russo, Domenico, additional

Published
2008
Full Text
View/download PDF

18. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis

Author

Cavazzini, Francesco, primary, Hernandez, Jose Angel, additional, Gozzetti, Alessandro, additional, Russo Rossi, Antonella, additional, De Angeli, Cristiano, additional, Tiseo, Ruana, additional, Bardi, Antonella, additional, Tammiso, Elisa, additional, Crupi, Rosaria, additional, Lenoci, Maria Pia, additional, Forconi, Francesco, additional, Lauria, Francesco, additional, Marasca, Roberto, additional, Maffei, Rossana, additional, Torelli, Giuseppe, additional, Gonzalez, Marcos, additional, Martin-Jimenez, Patricia, additional, Maria Hernandez, Jesus, additional, Rigolin, Gian Matteo, additional, and Cuneo, Antonio, additional

Published
2008
Full Text
View/download PDF

19. High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia

Author

Forconi, Francesco, primary, Poretti, Giulia, additional, Kwee, Ivo, additional, Sozzi, Elisa, additional, Rossi, Davide, additional, Rancoita, Paola M. V., additional, Capello, Daniela, additional, Rinaldi, Andrea, additional, Zucca, Emanuele, additional, Raspadori, Donatella, additional, Spina, Valeria, additional, Lauria, Francesco, additional, Gaidano, Gianluca, additional, and Bertoni, Francesco, additional

Published
2008
Full Text
View/download PDF

21. Case?control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients

Author

Malagola, Michele, primary, Damiani, Daniela, additional, Martinelli, Giovanni, additional, Michelutti, Angela, additional, Cesana, Bruno, additional, Vivo, Antonio De, additional, Piccaluga, Pier Paolo, additional, Ottaviani, Emanuela, additional, Candoni, Anna, additional, Geromin, Antonella, additional, Tiribelli, Mario, additional, Fanin, Renato, additional, Testoni, Nicoletta, additional, Lauria, Francesco, additional, Bocchia, Monica, additional, Gobbi, Marco, additional, Pierri, Ivana, additional, Zaccaria, Alfonso, additional, Zuffa, Eliana, additional, Mazza, Patrizio, additional, Priccolo, Giancarla, additional, Gugliotta, Luigi, additional, Bonini, Alessandro, additional, Visani, Giuseppe, additional, Skert, Cristina, additional, Bergonzi, Cesare, additional, Roccaro, Aldo Maria, additional, Filí, Carla, additional, Baccarani, Michele, additional, and Russo, Domenico, additional

Published
2007
Full Text
View/download PDF

23. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients

Author

Russo, Domenico, primary, Malagola, Michele, additional, Vivo, Antonio, additional, Fiacchini, Mauro, additional, Martinelli, Giovanni, additional, Piccaluga, Pier P., additional, Damiani, Daniela, additional, Candoni, Anna, additional, Michielutti, Angela, additional, Castelli, Maurizio, additional, Testoni, Nicoletta, additional, Ottaviani, Emanuela, additional, Rondoni, Michela, additional, Pricolo, Giancarla, additional, Mazza, Patrizio, additional, Zuffa, Eliana, additional, Zaccaria, Alfonso, additional, Raspadori, Donatella, additional, Bocchia, Monica, additional, Lauria, Francesco, additional, Bonini, Alessandro, additional, Avanzini, Paolo, additional, Gugliotta, Luigi, additional, Visani, Giuseppe, additional, Fanin, Renato, additional, and Baccarani, Michele, additional

Published
2005
Full Text
View/download PDF

24. Antibody binding capacity for evaluation of MDR‐related proteins in acute promyelocytic leukemia: Onset versus relapse expression

Author

Damiani, Daniela, primary, Michieli, Mariagrazia, additional, Michelutti, Angela, additional, Candoni, Anna, additional, Stocchi, Raffaella, additional, Masolini, Paola, additional, Geromin, Antonella, additional, Michelutti, Teresa, additional, Raspadori, Donatella, additional, Ippoliti, Micaela, additional, Lauria, Francesco, additional, and Fanin, Renato, additional

Published
2004
Full Text
View/download PDF

25. Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency

Author

Forconi, Francesco, primary, Capello, Daniela, additional, Berra, Eva, additional, Rossi, Davide, additional, Gloghini, Annunziata, additional, Cerri, Michaela, additional, Muti, Giuliana, additional, Morra, Enrica, additional, Paulli, Marco, additional, Magrini, Umberto, additional, Lucioni, Marco, additional, Rambaldi, Alessandro, additional, Lauria, Francesco, additional, Carbone, Antonino, additional, Stevenson, Freda K., additional, and Gaidano, Gianluca, additional

Published
2004
Full Text
View/download PDF

29. P‐glycoprotein (PGP) and lung resistance‐related protein (LRP) expression and function in leukaemic blast cells

Author

MICHIELI, MARIAGRAZIA, primary, DAMIANI, DANIELA, additional, ERMACORA, ANNA, additional, RASPADORI, DONATELLA, additional, MICHELUTTI, ANGELA, additional, GRIMAZ, STEFANIA, additional, FANIN, RENATO, additional, RUSSO, DOMENICO, additional, LAURIA, FRANCESCO, additional, MASOLINI, PAOLA, additional, and BACCARANI, MICHELE, additional

Published
1997
Full Text
View/download PDF

32. The inhibitory effect of serum from hairy-cell leukaemia patients on normal progenitor cells may disappear following prolonged treatment with α-interferon

Author

Lauria, Francesco, primary, Bagnara, Gian Paolo, additional, Catani, Lucia, additional, Gaggioli, Licia, additional, Guarini, Anna, additional, Raspadori, Donatella, additional, Foa, Robert, additional, Bellone, Graziella, additional, Buzzi, Marina, additional, Gugliotta, Luigi, additional, Zauli, Giorgio, additional, Giovannini, Marco, additional, Luigi zinzani, Pier, additional, and Tura, Sante, additional

Published
1989
Full Text
View/download PDF

36. Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.

Author

Defina M, Ippoliti M, Gozzetti A, Abruzzese E, Castagnetti F, Crupi R, Tiribelli M, Breccia M, Salvucci M, Aprile L, Baratè C, Gozzini A, Rosti G, Lauria F, and Bocchia M

Subjects
Adult, Aged, Aged, 80 and over, Bone Marrow Cells pathology, Female, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Leukemia, Myeloid, Chronic-Phase drug therapy, Leukemia, Myeloid, Chronic-Phase genetics, Leukemia, Myeloid, Chronic-Phase pathology, Male, Middle Aged, Antigens, CD34 metabolism, Antineoplastic Agents therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Neoplastic Stem Cells pathology, Protein Kinase Inhibitors therapeutic use, Pyrimidines therapeutic use
Abstract

Background: Compared with imatinib, nilotinib is a potent breakpoint cluster region/v-abl Abelson murine leukemia viral oncogene (bcr-abl) kinase inhibitor, and it induces higher rate and rapid complete cytogenetic response (CCyR), yet no clinical data are available regarding its efficacy against chronic myeloid leukemia (CML) stem cells. Earlier studies demonstrated that clusters of differentiation 34-positive, Philadelphia chromosome-positive (CD34(+) Ph(+) ) cells are detectable in about 45% of patients with CML, despite being on long-term imatinib therapy and having achieved sustained CCyR., Methods: CD34(+) cells from bone marrow of de novo CML patients in the chronic phase (n = 24) treated with nilotinib (median duration of therapy, 22 months) were isolated and scored for BCR-ABL by fluorescent in situ hybridization (FISH) analysis. Similar analysis was also performed in 5 de novo CML chronic phase patients who achieved CCyR within 3 months of nilotinib therapy., Results: FISH evaluation of a median of 100 CD34(+) nuclei per patient revealed that only 1 of 20 (5%) evaluable patients showed residual Ph(+) progenitor cells. In this patient, just 1 of 140 (0.7%) CD34(+) interphase nuclei was found to be positive for BCR-ABL. Surprisingly, no CD34(+) Ph(+) cells were found even in those 5 patients evaluated after 3 months of nilotinib treatment., Conclusions: This study assessed for the first time the persistence of CD34(+) Ph(+) cells during nilotinib first-line treatment. Preliminary results showed that in patients in CCyR, even after short-term nilotinib therapy, residual leukemic progenitors are very rarely detected compared with imatinib-treated CCyR patients. It is yet to be determined if these findings will have an impact in the path to a cure of CML with tyrosine kinase inhibitors., (Copyright © 2012 American Cancer Society.)

Published
2012
Full Text
View/download PDF

37. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.

Author

Gozzetti A, Cerase A, Lotti F, Rossi D, Palumbo A, Petrucci MT, Patriarca F, Nozzoli C, Cavo M, Offidani M, Floridia M, Berretta S, Vallone R, Musto P, Lauria F, Marchini E, Fabbri A, Oliva S, Zamagni E, Sapienza FG, Ballanti S, Mele G, Galli M, Pirrotta MT, and Di Raimondo F

Subjects
Adult, Aged, Aged, 80 and over, Brain Neoplasms mortality, Disease-Free Survival, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Multiple Myeloma mortality, Multivariate Analysis, Retrospective Studies, Brain Neoplasms drug therapy, Multiple Myeloma drug therapy
Abstract

Background: Intracranial involvement in multiple myeloma is extremely rare. The effect of new drugs (eg, thalidomide, bortezomib, lenalidomide) with respect to old drugs (eg, alkylators, steroids) has not been reported., Methods: We collected clinical and biological data of patients presenting with an osteo-dural or primary dural multiple myeloma (OD-DMM) or a central nervous system myelomatosis (CNS-MM) by sending a questionnaire to the centers of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA)., Results: A total of 50 patients were registered. New therapies were used in 35 patients, whereas 15 patients received old treatments. Twenty-five out of 50 patients obtained a complete remission or a very good partial remission (CR+VGPR). Overall survival (OS) for CNS-MM was 6 months, for OD-DMM 25 months. OS was 25 months for patients treated with new agents versus 8 months with old agents. Improved OS and progression-free survival were predicted by response (CR+VGPR) and by patients who underwent stem cell transplantation versus chemotherapy. β2-Microglobulin >5 mmol/L was a poor prognostic factor. Multivariate analysis showed poor survival for patients with β2-microglobulin >5 mmol/L and better survival for patients achieving CR+VGPR., Conclusions: The overall data highlight the relevance of therapy with new drugs in intracranial myeloma, providing a framework for future clinical trials., (Copyright © 2011 American Cancer Society.)

Published
2012
Full Text
View/download PDF

38. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.

Author

Rigacci L, Fabbri A, Puccini B, Chitarrelli I, Chiappella A, Vitolo U, Levis A, Lauria F, and Bosi A

Subjects
Aged, Antibodies, Monoclonal, Murine-Derived, Cytarabine administration & dosage, Disease-Free Survival, Drug Resistance, Neoplasm, Female, Hodgkin Disease mortality, Humans, Lymphoma, B-Cell mortality, Male, Middle Aged, Oxaliplatin, Recurrence, Rituximab, Salvage Therapy, Treatment Outcome, Antibodies, Monoclonal administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Dexamethasone administration & dosage, Hodgkin Disease drug therapy, Lymphoma, B-Cell drug therapy, Organoplatinum Compounds administration & dosage
Abstract

Background: Patients affected by relapsed or primary refractory lymphomas currently have a poor prognosis and no standard salvage treatment options. This study was carried out to assess the efficacy and safety of a dexamethasone, high-dose cytarabine, and oxaliplatin as salvage therapy in those patients, replacing cisplatin with oxaliplatin in the standard dexamethasone, cytarabine, and cisplatin scheme., Methods: Seventy patients with relapsed or refractory aggressive non-Hodgkin or Hodgkin lymphoma were treated from September 2001 to September 2007. The median age of patients was 51 years (range, 19-75 years). Histological subtypes were: diffuse large B-cell lymphoma (n=47) and Hodgkin lymphoma (n=23). The overall response rate was 73% (51 of 70), with 30 (43%) complete remissions and 21 (30%) partial remissions. Fifty-two patients were treated with dexamethasone, high-dose cytarabine, and oxaliplatin as second-line chemotherapy. Forty-eight patients were enrolled in an autologous stem cell transplantation program; forty (83%) finally proceeded to high-dose consolidation and autografting., Results: No grade 3 or 4 nonhematological toxicity was demonstrated; in particular, no renal or neurotoxicity was reported. After a median follow-up period of 21 months (range, 2-87 months), 22 (31%) patients had died. Probabilities of 2-year progression-free survival (PFS) and overall survival (OS) were 44% and 71%, respectively. In the chemosensitive patients, the PFS and OS were 52% and 83%, respectively. The only factor that significantly correlated with better OS was the response to therapy., Conclusions: This study confirms that dexamethasone, high-dose cytarabine, and oxaliplatin ± rituximab is an effective and feasible outpatient regimen for salvage therapy in patients affected by relapsed or refractory lymphoma. Moreover, the feasibility and efficacy of this scheme as an in vivo chemosensitive test in patients in autotransplantation programs was confirmed., (Copyright © 2010 American Cancer Society.)

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results